BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1320 related articles for article (PubMed ID: 32114718)

  • 1. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
    Yang J; Zhang C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved cancer immunotherapy strategies by nanomedicine.
    Guo S; Feng J; Li Z; Yang S; Qiu X; Xu Y; Shen Z
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(3):e1873. PubMed ID: 36576112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer.
    Saeed M; Chen F; Ye J; Shi Y; Lammers T; De Geest BG; Xu ZP; Yu H
    Adv Mater; 2021 Jul; 33(30):e2008094. PubMed ID: 34048101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano-Immune-Engineering Approaches to Advance Cancer Immunotherapy: Lessons from Ultra-pH-Sensitive Nanoparticles.
    Li S; Bennett ZT; Sumer BD; Gao J
    Acc Chem Res; 2020 Nov; 53(11):2546-2557. PubMed ID: 33063517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences.
    Chung CK; Da Silva CG; Kralisch D; Chan A; Ossendorp F; Cruz LJ
    J Control Release; 2018 Sep; 285():56-66. PubMed ID: 30008371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?
    Yuan CS; Deng ZW; Qin D; Mu YZ; Chen XG; Liu Y
    Acta Biomater; 2021 Apr; 125():1-28. PubMed ID: 33639310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy.
    Li W; Peng A; Wu H; Quan Y; Li Y; Lu L; Cui M
    Front Immunol; 2020; 11():601497. PubMed ID: 33408716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
    Liu J; Zhang R; Xu ZP
    Small; 2019 Aug; 15(32):e1900262. PubMed ID: 30908864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential applications of nanoparticles for tumor microenvironment remodeling to ameliorate cancer immunotherapy.
    Bai Y; Wang Y; Zhang X; Fu J; Xing X; Wang C; Gao L; Liu Y; Shi L
    Int J Pharm; 2019 Oct; 570():118636. PubMed ID: 31446027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy.
    Boone CE; Wang L; Gautam A; Newton IG; Steinmetz NF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 Jan; 14(1):e1739. PubMed ID: 34296535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biogenic nanoparticles as immunomodulator for tumor treatment.
    Cheng K; Kang Q; Zhao X
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Nov; 12(6):e1646. PubMed ID: 32464709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment.
    Sun B; Hyun H; Li LT; Wang AZ
    Acta Pharmacol Sin; 2020 Jul; 41(7):970-985. PubMed ID: 32424240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
    Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
    Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exosomes: Powerful weapon for cancer nano-immunoengineering.
    Pi YN; Xia BR; Jin MZ; Jin WL; Lou G
    Biochem Pharmacol; 2021 Apr; 186():114487. PubMed ID: 33647264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics.
    Grimaldi AM; Incoronato M; Salvatore M; Soricelli A
    Nanomedicine (Lond); 2017 Oct; 12(19):2349-2365. PubMed ID: 28868980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers.
    Mushtaq MU; Papadas A; Pagenkopf A; Flietner E; Morrow Z; Chaudhary SG; Asimakopoulos F
    J Immunother Cancer; 2018 Jul; 6(1):65. PubMed ID: 29970158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoengineered targeting strategy for cancer immunotherapy.
    Yin WM; Li YW; Gu YQ; Luo M
    Acta Pharmacol Sin; 2020 Jul; 41(7):902-910. PubMed ID: 32398683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.
    Peng S; Xiao F; Chen M; Gao H
    Adv Sci (Weinh); 2022 Jan; 9(1):e2103836. PubMed ID: 34796689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.